Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISTH0047
- Development stage
- Preclinical
- Lead developer
- Isarna Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ISTH0047 is a second-generation, phosphorothioate-locked nucleic acid (LNA)-modified antisense oligonucleotide (ASO) gapmer developed by Isarna Therapeutics. It specifically targets transforming growth factor-beta 2 (TGF-beta 2) mRNA, inhibiting its expression and downstream signaling pathways (such as SMAD2 phosphorylation). ISTH0047 is being investigated preclinically for oncology indications, including glioblastoma (glioma), renal cell carcinoma (RCC), breast cancer, and lung metastasis, where it has demonstrated the ability to reduce tumor cell migration, invasion, and metastasis, as well as modulate the tumor microenvironment.
02
Targets
TGFB2 (Transforming growth factor beta 2)
Beyond the preview
Go deeper on ISTH0047.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISTH0047.